Glucose lowering by SGLT2-inhibitor empagliflozin accelerates atherosclerosis regression in hyperglycemic STZ-diabetic mice

Diabetes worsens atherosclerosis progression and leads to a defect in repair of arteries after cholesterol reduction, a process termed regression. Empagliflozin reduces blood glucose levels via inhibition of the sodium glucose cotransporter 2 (SGLT-2) in the kidney and has been shown to lead to a ma...

Descripción completa

Detalles Bibliográficos
Autores principales: Pennig, Jan, Scherrer, Philipp, Gissler, Mark Colin, Anto-Michel, Nathaly, Hoppe, Natalie, Füner, Lisa, Härdtner, Carmen, Stachon, Peter, Wolf, Dennis, Hilgendorf, Ingo, Mullick, Adam, Bode, Christoph, Zirlik, Andreas, Goldberg, Ira J., Willecke, Florian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6884628/
https://www.ncbi.nlm.nih.gov/pubmed/31784656
http://dx.doi.org/10.1038/s41598-019-54224-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6884628/
https://www.ncbi.nlm.nih.gov/pubmed/31784656
http://dx.doi.org/10.1038/s41598-019-54224-9

Ejemplares similares